Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26618008 | 0.91 | OPRM1 (0.47) | HRH3GRIN2BKDM4EALDH1A1AGTR2 | |
| SCHEMBL21500916 | 0.88 | UBE2M (0.47) | HRH3GRIN2BKDM4EALDH1A1AGTR2 | |
| SCHEMBL8259453 | 0.85 | CHIA (0.53) | HRH3GRIN2BAGTR2CYP2D6CHRM1 | |
| SCHEMBL20950822 | 0.82 | CYP2D6 (0.45) | HRH3GRIN2BAGTR2KCNH2CYP2D6 | |
| SCHEMBL8258573 | 0.82 | KMT2A (0.49) | HRH3GRIN2BAGTR2HRH4SLC18A3 | |
| SCHEMBL8442356 | 0.82 | KDM4E (0.68) | HRH3GRIN2BKDM4EALDH1A1AGTR2 | |
| SCHEMBL22878155 | 0.82 | GRIN2B (0.52) | HRH3GRIN2BKDM4EALDH1A1AGTR2 | |
| SCHEMBL12013096 | 0.82 | KMT2A (0.51) | HRH3GRIN2BKDM4EALDH1A1KCNH2 | |
| SCHEMBL3771082 | 0.82 | HRH3 (0.51) | HRH3ALDH1A1AGTR2KCNH2CHRM1 | |
| SCHEMBL3375289 | 0.81 | GRIN2B (0.61) | HRH3GRIN2BKDM4EALDH1A1HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827641-B2 | Toll-like receptor antagonist compounds and methods of use | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2023-11-28 | — | — | US | disclosed |
| US-11370794-B2 | Toll-like receptor antagonist compounds and methods of use | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2022-06-28 | — | — | US | disclosed |
| US-20190345161-A1 | TOLL-LIKE RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USE | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2019-11-14 | — | — | US | disclosed |
| US-7256186-B2 | Gamma secretase inhibitors | SCHERING CORPORATION (US) | 2007-08-14 | — | — | US | disclosed |
| US-7208602-B2 | Gamma secretase inhibitors | SCHERING CORPORATION (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208602-B2 | Gamma secretase inhibitors | SCHERING CORPORATION (US) | 2007-04-24 | — | — | US | disclosed |
| US-20050085506-A1 | Novel gamma secretase inhibitors | SCHERING-PLOUGH CORPORATION AND PHARMACOPEIA, INC. | 2005-04-21 | — | — | US | disclosed |
| US-20040171614-A1 | Novel gamma secretase inhibitors | SCHERING-PLOUGH CORPORATION | 2004-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171614-A1 | Novel gamma secretase inhibitors | BACE1, BACE2, APP | HRH3 789/4885GRIN2B 289/4885KDM4E 2433/4885 |
| US-11827641-B2 | Toll-like receptor antagonist compounds and methods of use | TLR7, TLR9, TLR1 | HRH3 355/4885GRIN2B 598/4885KDM4E 1755/4885 |
| US-20190345161-A1 | TOLL-LIKE RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USE | TLR7, TLR9, TLR1 | HRH3 355/4885GRIN2B 598/4885KDM4E 1755/4885 |
| US-11370794-B2 | Toll-like receptor antagonist compounds and methods of use | TLR9, TLR7, TLR8 | HRH3 420/4885GRIN2B 751/4885KDM4E 1212/4885 |
| US-20050085506-A1 | Novel gamma secretase inhibitors | BACE1, BACE2, APP | HRH3 278/4885GRIN2B 177/4885KDM4E 2865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.